{
  "ticker": "ARDX",
  "company_name": "Ardelyx, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03824587",
      "title": "Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy",
      "status": "COMPLETED",
      "phase": "PHASE2, PHASE3",
      "condition": "Hyperphosphatemia",
      "start_date": "2019-02-28",
      "completion_date": "2019-07-17",
      "enrollment": 0,
      "sponsor": "Ardelyx"
    },
    {
      "nct_id": "NCT02226783",
      "title": "D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers Food Interaction Study",
      "start_date": "2013-03",
      "completion_date": "2013-10",
      "enrollment": 0,
      "sponsor": "Ardelyx"
    },
    {
      "nct_id": "NCT01764854",
      "title": "Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "End Stage Renal Disease, Chronic Kidney Disease Stage 5, ESRD",
      "start_date": "2013-01",
      "completion_date": "2013-10",
      "enrollment": 0,
      "sponsor": "Ardelyx"
    },
    {
      "nct_id": "NCT02621892",
      "title": "A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Constipation Predominant Irritable Bowel Syndrome",
      "start_date": "2015-10",
      "completion_date": "2017-04",
      "enrollment": 0,
      "sponsor": "Ardelyx"
    },
    {
      "nct_id": "NCT03427125",
      "title": "A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Hyperphosphatemia",
      "start_date": "2018-01-08",
      "completion_date": "2020-02-27",
      "enrollment": 0,
      "sponsor": "Ardelyx"
    },
    {
      "nct_id": "NCT06553547",
      "title": "4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Irritable Bowel Syndrome With Constipation (IBS-C)",
      "start_date": "2024-07-24",
      "completion_date": "2026-06",
      "enrollment": 0,
      "sponsor": "Ardelyx"
    },
    {
      "nct_id": "NCT02796131",
      "title": "Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2011-07",
      "completion_date": "2012-04",
      "enrollment": 0,
      "sponsor": "Ardelyx"
    },
    {
      "nct_id": "NCT05905926",
      "title": "Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "PHASE3",
      "condition": "Irritable Bowel Syndrome With Constipation (IBS-C)",
      "start_date": "2023-02-17",
      "completion_date": "2031-10",
      "enrollment": 0,
      "sponsor": "Ardelyx"
    },
    {
      "nct_id": "NCT03018067",
      "title": "A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Hyperkalemia",
      "start_date": "2017-01",
      "completion_date": "2017-05",
      "enrollment": 0,
      "sponsor": "Ardelyx"
    },
    {
      "nct_id": "NCT02727751",
      "title": "A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Constipation Predominant Irritable Bowel Syndrome",
      "start_date": "2016-03",
      "completion_date": "2017-10",
      "enrollment": 0,
      "sponsor": "Ardelyx"
    }
  ],
  "summary": {
    "total_trials": 31,
    "by_phase": {
      "PHASE2, PHASE3": 2,
      "PHASE1": 10,
      "PHASE2": 8,
      "PHASE3": 8,
      "PHASE4": 3
    },
    "by_status": {
      "COMPLETED": 24,
      "RECRUITING": 4,
      "ENROLLING_BY_INVITATION": 1,
      "TERMINATED": 1,
      "ACTIVE_NOT_RECRUITING": 1
    },
    "active_trials": 6,
    "completed_trials": 24,
    "conditions": [
      "Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia",
      "Chronic Kidney Disease, Type 2 Diabetes Mellitus",
      "Constipation Predominant Irritable Bowel Syndrome",
      "Cystic Fibrosis, Constipation",
      "End Stage Renal Disease, Chronic Kidney Disease Stage 5, ESRD",
      "Healthy",
      "Healthy Volunteer",
      "Healthy Volunteers",
      "Healthy Volunteers Food Interaction Study",
      "Hyperkalemia",
      "Hyperphosphatemia",
      "Hyperphosphatemia, End Stage Renal Disease",
      "IBS, IBS - Irritable Bowel Syndrome",
      "Irritable Bowel Syndrome With Constipation (IBS-C)",
      "Lactation",
      "Synucleinopathy, Parkinson's Disease"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:16:32.926906",
    "search_query": "Ardelyx, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Ardelyx,+Inc."
  }
}